Form 4: Director Barlow Converts RSUs to Supernus Stock

Supernus Pharmaceuticals Director Carrolee Barlow converted 4,475 restricted stock units into common stock, increasing her direct beneficial ownership.

Summary

• Carrolee Barlow, a Director of Supernus Pharmaceuticals, Inc. (SUPN), acquired 4,475 shares of common stock.
• This acquisition resulted from the vesting and settlement of 4,475 restricted stock units (RSUs).
• The transaction occurred on February 24, 2026, with a price of $0 per share, typical for RSU vesting.
• Following this transaction, Ms. Barlow directly beneficially owns 27,045 shares of Supernus common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine compensation action that increases director ownership, aligning interests, but does not signal new strategic developments.

Positives

• Director Carrolee Barlow's beneficial ownership of Supernus common stock increased by 4,475 shares, demonstrating continued alignment with shareholder interests.
• The conversion of Restricted Stock Units (RSUs) into common stock indicates a scheduled vesting event, a normal part of executive compensation.

Negatives

• No direct negatives are apparent from this routine RSU vesting and conversion transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU vesting and conversion, are common across the pharmaceutical industry. These events typically reflect pre-scheduled compensation plans and are generally not indicative of a change in company fundamentals or strategic direction, unlike open market purchases or sales which might signal management's view on valuation.

Comparison to Industry Standards

• This transaction is a standard RSU vesting event, which is a common component of executive and director compensation packages across publicly traded companies, including those in the pharmaceutical sector.
• It aligns with typical compensation structures seen at peers like Biogen Inc. or Eli Lilly and Company, where equity awards are used to align management incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: Increased director ownership may be viewed positively as it aligns management's interests with long-term shareholder value.
• Employees: This transaction is part of a standard equity compensation plan, which can be a positive for employee retention and motivation.

Key Dates

Recommendation

This Form 4 filing details a routine RSU vesting and conversion for a director, which is a standard compensation event and does not provide new material information to warrant a change in investment recommendation. It reflects a pre-scheduled equity award rather than a discretionary purchase or sale based on new insights into the company's prospects. Therefore, a 'hold' recommendation is appropriate as the filing itself does not alter the fundamental investment thesis for Supernus Pharmaceuticals.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Stock Ownership, Carrolee Barlow